Comparative Pharmacology
Head-to-head clinical analysis: CAM AP ES versus DIMETHYL SULFOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAM AP ES versus DIMETHYL SULFOXIDE.
CAM-AP-ES vs DIMETHYL SULFOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAM-AP-ES is a combination antihypertensive containing camphor, apocynum, and eserine. The mechanism involves camphor as a mild vasodilator, apocynum as a cardiac glycoside with positive inotropic and negative chronotropic effects, and eserine as a cholinesterase inhibitor that enhances parasympathetic activity, leading to reduced heart rate and vasodilation.
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
CAM-AP-ES: Oral, 1-2 tablets twice daily. Each tablet contains camphor 30 mg, apomorphine 5 mg, and eserine 2 mg.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
None Documented
None Documented
Clinical Note
moderateDimethyl sulfoxide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide."
Clinical Note
moderateDimethyl sulfoxide + Atorvastatin
"The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin."
Clinical Note
moderateDimethyl sulfoxide + Dexrazoxane
"The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide."
Clinical Note
moderateTerminal elimination half-life 10–12 hours in normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Terminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
Renal: ~90% unchanged drug; biliary/fecal: ~10% as metabolites
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Category C
Category C
Topical Analgesic
Topical Analgesic
Metoprolol + Dimethyl sulfoxide
"The serum concentration of Dimethyl sulfoxide can be increased when it is combined with Metoprolol."